13 completed, 1 unknown. 6 Phase 3, 5 Phase 4, 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 4 | 5 | Completed 4, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow bepotastine besilate: new trials by email Literature Review of bepotastine besilate trials Research Report on bepotastine besilate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK - Allergic Conjunctivitis | Phase 4 | Completed | Laboratorios Poen | 97 | 2021-03-10 | 2022-12-15 |
| Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Bepotastine Besilate - Safety, Tolerability | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 22 | 2020-09-24 | 2025-07-16 |
| A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis Bepotastine besilate - Perennial Allergic Rhinitis | Phase 3 | Completed | Tanabe Pharma Corporation | 58 | 2013-06-01 | 2026-01-07 |
| The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis Bepotastine besilate, Placebo - Perennial Allergic Rhinitis | Phase 3 | Completed | Tanabe Pharma Corporation | 473 | 2013-04-01 | 2026-01-08 |
| A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis Bepotastine besilate, ketotifen fumarate - Dermatitis, Atopic | Phase 3 | Completed | Tanabe Pharma Corporation | 303 | 2013-03-01 | 2026-01-08 |
| Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) Bepotastine besilate, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Bausch & Lomb Incorporated | 617 | 2013-01-01 | 2020-10-05 |
| Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis bepotastine besilate, 1.5%, Loteprednol etabonate - Allergic Conjunctivitis | Phase 4 | Completed | Southern California College of Optometry at Marshall B. Ketchum University | 23 | 2011-10-01 | 2019-08-06 |
| Comparing Patient Satisfaction With Pataday or Bepreve Olopatadine hydrochloride 0.2%, Bepotastine besilate ophthalmic solution 1.5% - Eye Allergies | Not applicable | Completed | McCabe Vision Center | 30 | 2011-09-01 | 2014-01-09 |
| Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Bepotastine - Allergic Conjunctivitis | Phase 4 | Unknown | Hom, Milton M., OD, FAAO | 24 | 2011-05-01 | 2011-04-19 |
| The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution - Allergic Conjunctivitis | Phase 4 | Completed | Minnesota Eye Consultants, P.A. | 40 | 2011-05-01 | 2020-03-31 |
| The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Bepreve, Refresh Tears - Histamine Responsive Allergy Patients | Phase 4 | Completed | North Texas Institute for Clinical Trials | 30 | 2010-04-01 | 2010-07-08 |
| Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers Bepreve, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 861 | 2007-10-01 | 2013-02-15 |
| Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 130 | 2007-10-01 | 2013-02-08 |
| Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Bepreve, Placebo, Bepotastine Besilate - Conjunctivitis, Allergic | Phase 2 / Phase 3 | Completed | Bausch & Lomb Incorporated | 107 | 2007-02-01 | 2013-02-15 |
Conjunctivitis, Allergic (8) · Conjunctivitis (2) · Rhinitis, Allergic, Perennial (2) · Dermatitis (1) · Hypersensitivity (1) · Pruritus (1) · Rhinitis, Allergic, Seasonal (1)
Bausch & Lomb Incorporated (4) · Tanabe Pharma Corporation (3) · Hom, Milton M., OD, FAAO (1) · Laboratorios Poen (1) · Laboratorios Sophia S.A de C.V. (1) · McCabe Vision Center (1) · Minnesota Eye Consultants, P.A. (1) · North Texas Institute for Clinical Trials (1) · Southern California College of Optometry at Marshall B. Ketchum University (1)
United States (7) · Japan (3) · Argentina (1) · Mexico (1)
Tim McNamara, PharmD (2) · Ahmad M Fahmy, O.D. (1) · Bob Q Lanier, MD (1) · Jon Williams, Ph.D. (1) · Jon Williams, PhD (1) · Judy Tong, OD (1) · Milton M Hom, OD FAAO (1)
PMID 22991696, PMID 26364765, PMID 19843481, PMID 20488431, PMID 20642205